[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351494-105":59,"doc-detail-351494-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rheumatic-immune-related-adverse-effects-of-immune-checkpoint-treatment-a-retrospective-multicentre-study","Rheumatic immune-related adverse effects of immune checkpoint treatment - a retrospective multicentre study","","Rheumatic immune-related adverse events (R-irAEs) in patients receiving immune checkpoint inhibitors (ICIs) were characterized in a retrospective observational multicentre study at two oncology centers in Spain. Electronic medical records identified R-irAEs with rheumatologist-confirmed diagnoses among 734 ICI-treated patients from January 2016 to December 2022. Any irAEs occurred in 30.9%, while R-irAEs accounted for 7.35% and 23.8% of all irAEs, typically within six months. Corticosteroids were primary treatment; 88% improved, but 18 required ICI discontinuation. Findings emphasize early recognition and multidisciplinary management, plus standardized guidelines.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rheumatic-immune-related-adverse-effects-of-immune-checkpoint-treatment-a-retrospective-multicentre-study/351494/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rheumatic-immune-related-adverse-effects-of-immune-checkpoint-treatment-a-retrospective-multicentre-study/351494.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim regarding rheumatic irAEs?","Question",{"text":112,"@type":113},"To describe the frequency, clinical spectrum, and management of rheumatic immune-related adverse events in patients receiving immune checkpoint inhibitors at two oncology centers in Spain.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How common were rheumatic immune-related adverse events in the cohort?",{"text":117,"@type":113},"Among 734 patients, 30.9% developed any irAEs, and 7.35% presented R-irAEs, which represented 23.8% of all irAEs.",{"name":119,"@type":110,"acceptedAnswer":120},"When did rheumatic immune-related adverse events most often occur and how were they treated?",{"text":121,"@type":113},"Most R-irAEs occurred within six months of ICI initiation. Corticosteroids were the primary treatment, with some patients requiring immunosuppressants, biologics, or intravenous immunoglobulins.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351494,1790465205,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study  \nArturo Llobell-Uriel1,6􀀍, Íñigo González-Mazón2, Jordi Gratacós1, Soledad Retamozo1,  \nCarmen Secada-Gómez2, Adrian Martín-Gutiérrez2, Almudena García-Castaño3, Luis Fernández-Morales4, Enrique Gallardo-Diaz4, Antoni Berenguer-Llergo1, Jorge del Estal-Jiménez5, Javier Delgado-Rodríguez5, Antonio Gómez-Centeno1, Miguel Angel Segui-Palmer4, Ricardo Blanco2 & Joan Calvet1,6  \nTo describe the frequency, clinical spectrum, and management of rheumatic immune-related adverse events (R-irAEs) in patients receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain. This was a retrospective, observational study involving 734 patients treated with ICIs between January 2016 and December 2022 in two Spanish hospitals. Electronic medical records were systematically reviewed to identify R-irAEs, with diagnoses confirmed by rheumatologists. The data collected included demographics, cancer type, ICI regimen, time to R-irAE onset, clinical features, management, and outcomes. Among the 734 patients, 227 (30.9%) developed any irAEs, with 54 (7.35%) presenting R-irAEs, accounting for 23.8% of all irAEs. The most common cancers were lung cancer and melanoma. Most R-irAEs occurred within six months of ICI initiation. The most frequent manifestations were polymyalgia rheumatica (n = 12) and various forms of arthritis/arthralgia (n = 26) . Myositis is a particularly severe manifestation that presents at the first or second cycle of treatment. Corticosteroids are the primary treatment, with some patients requiring immunosuppressants, biologics, or intravenous immunoglobulins. Clinical improvement was observed in 88% of the treated patients, although 18 patients required ICI discontinuation due to toxicity. The increasing use of ICIs in cancer treatment is limited by development of irAEs (30.9%) and R-irAEs (7.35%) accounting for 23.8% of irAEs. Prompt recognition and multidisciplinary management, including rheumatology input, are essential to optimize patient outcomes and balance the continuation of cancer treatment. Greater awareness and standardized guidelines are needed to improve the diagnosis and care of these adverse events.  \nKeywords Immune checkpoint inhibitors (ICIs), Rheumatic immune-related adverse events, Inflammatory arthritis, Polymyalgia rheumatica, Myositis, Cancer immunotherapy  \nImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment in the past decade, offering patients novel therapeutic options and, in many cases, significantly improving clinical outcomes. ICIs, such as antagonists of programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4), exert their effects by restoring the immune system’s ability to recognize and eliminate cancer cells1,2. However, modulating the immune system may also lead to complications known as immune-related adverse events (irAEs) .  \n1Department of Rheumatology, Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PTCERCA), Universitat Autònoma de Barcelona Medicine Department, Parc del Taulí, 1, Sabadell 08208, Spain.  \n2Department of Rheumatology, Marqués deValdecilla University Hospital, IDIVAL, Santander, Spain. 3Department of Oncology, Marqués deValdecilla University Hospital, IDIVAL, Santander, Spain. 4Department of Oncology, Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona Medicine Department, Sabadell, Spain. 5Department of Pharmacy, ParcTaulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona Medicine Department, Sabadell, Spain. 6Arturo Llobell-Uriel and Joan Calvet contributed equally to this work. 􀀍 email: [artack@gmail.com](ar","cbCaisFWdaV2UJjJ","https://ap.wps.com/l/cbCaisFWdaV2UJjJ","pdf",1261086,"English","# Study objective\n# Study design and patient selection\n# Case identification and data collection\n# Incidence and timing of R-irAEs\n# Clinical manifestations and severity\n# Treatment approaches and outcomes\n# Discussion and clinical implications","[{\"question\":\"What was the study aim regarding rheumatic irAEs?\",\"answer\":\"To describe the frequency, clinical spectrum, and management of rheumatic immune-related adverse events in patients receiving immune checkpoint inhibitors at two oncology centers in Spain.\"},{\"question\":\"How common were rheumatic immune-related adverse events in the cohort?\",\"answer\":\"Among 734 patients, 30.9% developed any irAEs, and 7.35% presented R-irAEs, which represented 23.8% of all irAEs.\"},{\"question\":\"When did rheumatic immune-related adverse events most often occur and how were they treated?\",\"answer\":\"Most R-irAEs occurred within six months of ICI initiation. Corticosteroids were the primary treatment, with some patients requiring immunosuppressants, biologics, or intravenous immunoglobulins.\"}]","Rheumatic immune-related adverse effects of immune checkpoint treatment - a retrospective multicentre study | PDF",1790094411,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7534c0a2cb794cb005bf63c0ab58ccfc.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c9236d1c546ded3a224c066e4afbb27.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1371045c7e0df88782002e3c698a444b.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c7c6c77291bcbd59802f73227694700.webp",980,1287]